Day 2 of the 2nd EAU Update on Prostate Cancer (PCa18) has further expanded its discussion of key topics that impact on the diagnosis and clinical management of malignant prostate disease. Participants are challenged with new approaches, insights on best practices and future prospects.
Dr.Gina Torres-Zambrano from Madrid, Spain, talked about her impressions on PCa18. She is currently specialising in female urology, but also has plans to later move on to onco-urology.
Q: What made you decide to attend this meeting?
Torres-Zambrano: As a specialist in female urology, I realized I have a lack of knowledge on prostate cancer. When I received the invitation I thought it was a really interesting update meeting. There are so many changes in prostate cancer and the developments are happening so fast that I was convinced it is necessary to get an update. Besides, I have plans to move into oncology, so this meeting is definitely helpful.
Q: What key messages from the lectures and case discussions that you find remarkable or significant?
Torres-Zambrano: That’s difficult to answer because the range of the topics discussed was not only extensive but also very varied. Firstly, prostate cancer is a challenging disease to treat with many approaches, both medical and surgical. After all the lectures and the discussions, I find it hard to choose a particular issue. But my attention is drawn to the dilemma of choosing an optimal therapy since there are many ways to manage a particular case. Should we intervene in time or not? What is the optimal timing for a certain drug? These are questions that don’t have an easy answer but are often in the grey areas.
Q: Would you return for a similar update meeting?
Torres-Zambrano: Yes, certainly, because not only is it a complete update meeting but it is also a challenging one that makes the participant think twice about the effectiveness of an established therapy compared to a novel strategy. We definitely need these update meetings with all the fast changes and developments happening now in cancer therapies